Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Tango Therapeutics, Inc. (TNGX) reported a Q3 loss of $0.27 per share, which was better than the Zacks Consensus Estimate of a $0.34 loss. This is a slight increase in loss compared to $0.23 per share a year ago.
November 06, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics reported a Q3 loss of $0.27 per share, better than the expected $0.34 loss, indicating a positive surprise for investors despite a year-over-year increase in loss.
The better-than-expected earnings report is likely to have a positive short-term impact on TNGX's stock price. Although the loss increased compared to last year, beating the consensus estimate is a positive indicator for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100